Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063095 | 0.86 | PDE4A (0.39) | RORCCYP2C9PDE4AKCNH2ELANE | |
| SCHEMBL4061518 | 0.81 | PDE4A (0.41) | RORCPDE4AKCNH2ELANEHTR3A | |
| SCHEMBL4060222 | 0.80 | PDE4A (0.39) | RORCCYP2C9PDE4AKCNH2ELANE | |
| SCHEMBL4069712 | 0.80 | KDM4E (0.46) | RORCPDE4AKCNH2HTR3ACNR1 | |
| SCHEMBL4060598 | 0.80 | SMN1; SMN2 (0.42) | RORCPDE4AKCNH2ELANE | |
| Hydrochloric Acid SCHEMBL4063788 | 0.79 | SMN1; SMN2 (0.42) | RORCPDE4AKCNH2ELANE | |
| SCHEMBL4068255 | 0.78 | SLC9A1 (0.41) | RORCPDE4AKCNH2ELANE | |
| SCHEMBL4058462 | 0.78 | HTR3A (0.54) | PDE4AKCNH2ELANEHTR3ACNR1 | |
| SCHEMBL4058513 | 0.78 | KCNH2 (0.47) | RORCPDE4AKCNH2HTR3ACNR1 | |
| SCHEMBL4062806 | 0.78 | PDE4A (0.40) | PDE4AKCNH2ELANEHTR3ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641791-B1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | claimed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | claimed |
| EP-1641791-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| WO-2004111048-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | claimed |
| EP-1641791-B1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | TNNI3, TNNT2, TNNC1 | RORC 1476/4885CYP2C9 672/4885PDE4A 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.